ijerph-logo

Journal Browser

Journal Browser

HIV and Other Infectious Diseases

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Infectious Disease Epidemiology".

Deadline for manuscript submissions: closed (28 March 2023) | Viewed by 1774

Special Issue Editor


E-Mail Website
Guest Editor
Department of Social Medicine and Health Education, School of Public Health, Peking University Health Science Center, Beijing 100191, China
Interests: HIV/AIDS; behavioral intervention; health promotion; health behavior theories; COVID-19; PrEP; mental health; infectious diseases; behavioral health and health promotion
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infectious diseases are one of the leading causes of morbidity and mortality in all parts of the world. Deaths from the infectious diseases HIV/AIDS have fallen significantly in recent years, but they are still a leading cause of death in low-income countries. COVID-19, caused by the virus SARS-CoV-2, became a top cause of death in 2020. Infectious diseases have plagued us throughout history, epidemics and pandemics have produced major social/economic impacts on populations.

Despite significant advances in infectious disease research and treatment, the control and eradication of infectious diseases face major challenges. This special issue welcomes submissions across the broadest interpretation of these issues, including, but definitely not restricted to, the following:

  • Prevention and treatment of HIV/AIDS, particularly among vulnerable subpopulations (e.g., LGBTQ+);
  • Infectious diseases control and prevention in different geographic regions, particularly low-come countries;
  • Behavioral interventions for infectious diseases control and prevention;
  • Mental health and social impacts of infectious diseases;

Both original research and systematic review papers are welcomed.

Dr. Wangnan Cao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV/AIDS
  • infectious diseases
  • COVID-19
  • monkeypox
  • LGBTQ
  • low-come countries
  • behavioral interventions
  • mental health
  • systematic review

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1612 KiB  
Article
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy
by Valentina Perrone, Melania Dovizio, Diego Sangiorgi, Margherita Andretta, Fausto Bartolini, Arturo Cavaliere, Andrea Ciaccia, Alessandro Chinellato, Alberto Costantini, Stefania Dell’Orco, Fulvio Ferrante, Simona Gentile, Antonella Lavalle, Rossella Moscogiuri, Elena Mosele, Cataldo Procacci, Davide Re, Fiorenzo Santoleri, Alessandro Roccia, Franco Maggiolo and Luca Degli Espostiadd Show full author list remove Hide full author list
Int. J. Environ. Res. Public Health 2023, 20(5), 3789; https://doi.org/10.3390/ijerph20053789 - 21 Feb 2023
Viewed by 1373
Abstract
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir [...] Read more.
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir Alafenamide (TAF)-based regimens on healthcare resource consumption and related direct healthcare costs. Between 2015 and 2019, adults (≥18 years) prescribed with TAF-based therapies were identified and characterized in the year prior to the first prescription (index-date) for TAF-based therapies and followed-up until the end of data availability. Overall, 2658 ART-treated patients were included, 1198 of which were under a TAF-based regimen. TAF-based therapies were associated with elevated percentages of adherence (83.3% patients with proportion of days covered, PDC > 95% and 90.6% with PDC > 85%) and persistence (78.5%). The discontinuation rate was low in TAF-treated patients, ranging from 3.3% in TAF-switchers to 5% in naïve. Persistent patients had lower overall mean annual healthcare expenditures (EUR 11,106 in persistent vs. EUR 12,380 in non-persistent, p = 0.005), and this trend was statistically significant also for costs related to HIV hospitalizations. These findings suggest that a better therapeutic management of HIV infection might result in positive clinical and economic outcomes. Full article
(This article belongs to the Special Issue HIV and Other Infectious Diseases)
Show Figures

Figure 1

Back to TopTop